The Future of Pain Relief

Investing is inherently a lazy man’s game.

You get no more points for solving a difficult problem than you would for solving a simple one.

So while NASA engineers may be looking for ways to land probes on passing asteroids or open wormholes, investors are always looking for the most straightforward — dare I say, obvious — methods for increasing their wealth.

Because after all, a 25% gain on something as boring as gold is just as good as a 25% gain on the hottest new tech trend.

Well, today I want to talk to you about a commercial trend that’s almost insultingly simple to spot and evaluate.

When it comes, it will surprise few analysts — except, perhaps, in its magnitude.

The trend has to do with a major medical problem in this country… a problem that is set to increase disproportionately in size as we move forward.

Want to Spot Trends? Look to Demographics

That problem is pain management.

Pain, unfortunately, is a fact of life for us all.

Whether it’s chronic or traumatic, the causes of pain tend to stack up over the years and increase in severity as we age.

And aging is at the heart of the problem.

You see, the Baby Boomer generation — which emerged in the years following World War II as the U.S. went through historically unprecedented economic and social development — is now hitting retirement age.

The number of Americans over the age of 65 is skyrocketing — and that’s set to continue for at least the next two decades.

This means a similar explosion in medical costs in the U.S. as this massive segment of the population goes through the painful and expensive process of growing old.

Aside from Alzheimer’s and other age-related degenerative diseases, chronic pain is among the greatest concerns for the elderly.

The true danger it poses is indirect, as chronic pain tends to promote inactivity and give rise to a host of other problems like muscle degradation and bone density loss.

So the problem is there, and the need for pain management has never been greater.

A New Supply for a Growing Demand

Now here’s the second, crucial variable of the equation.

Right now, there is a medical revolution going on in this country, and it involves one of nature’s greatest pain relievers.

You probably wouldn’t recognize the 10 or so syllables of its full chemical name, but in the industry, it’s known simply as “Delta-9.”

Used to treat chronic pain disorders and excruciating diseases like cancer and arthritis, “Delta-9,” in both its natural and processed form, has been a godsend to millions of people.

It’s far superior to the historically preferred opioid-derived methods of high-level pain management because it causes no chemical dependency and no nausea (in fact, it cures nausea), so it can therefore be used as a daily treatment for intermediate pain and even as an appetite booster for patients undergoing chemo or radiation therapy.

In fact, the only real drawback to “Delta-9” has been the FDA’s politically motivated reluctance to allow for complete, across-the-board approval for testing, experimentation, and commercialization.

Today, however, all that is slowly starting to change. “Delta-9” is currently going through a renaissance of sorts, as laws governing its use are relaxed nationwide.

Keeping it Simple

Make no mistake about it: These changes will bring about a shift in medical policy as surely as a massive new crude oil discovery would bring about a change in gas prices.

It is, without a doubt, one of the easiest-to-spot trends out there right now in any sector… And when viewed with the perspective of the expanding consumer base in the market of indefinite pain management, it’s pretty darn close to a perfect storm.

Like I said before, investment is best suited for the lazy man. No points for overthinking.

Here’s the problem: There are a lot of companies out there that see this potential and are trying to take advantage of this emerging industrial trend — which means that your risk, as an investor, is in the company you choose, not the idea itself.

But this isn’t a problem at all, actually.

You see, quite recently, my friend and the investment director of The Crow’s Nest, Jimmy Mengel, completed the most in-depth research I’ve seen on the topic of “Delta-9.”

He’s found not one but three companies that best leverage this trend — each of them very unique in its own right.

These companies run the gamut in terms of market capitalization, so you can decide how much risk you want. But in the end, they’re all involved in a no-lose scenario.

I honestly think “Delta-9” has the potential to change the face of modern medicine. In fact, I myself have spoken to doctors who were amazed it hasn’t happened sooner.

The time has come. Don’t miss your shot.

Click here for free, instant access to Jimmy’s full report.

Fortune favors the bold,

Alex Koyfman

Check us out on YouTube!

His flagship service, Microcap Insider, provides market-beating insights into some of the fastest moving, highest profit-potential companies available for public trading on the U.S. and Canadian exchanges. With more than 5 years of track record to back it up, Microcap Insider is the choice for the growth-minded investor. Alex contributes his thoughts and insights regularly to Energy and Capital. To learn more about Alex, click here.